secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-09-26T23:59:59+00:00
Accession:  0001437749-25-029907
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Suitability Petition for NRx's preservative-free ketamine, enabling ANDA re-filing
--------------------------------------------------------------------------------

- FDA approved Suitability Petition for proposed strength of NRx's single-patient, preservative-free ketamine (KETAFREE™).
- Currently marketed ketamine uses multi-dose vials with toxic preservative Benzethonium Chloride; KETAFREE™ is preservative-free.
- Suitability Petition grant enables immediate re-filing of Abbreviated New Drug Application (ANDA) for KETAFREE™.
- NRx estimates total ketamine market at $750M; product aligns with FDA/HHS policy on removing toxic preservatives.
- NRx CEO noted rapid FDA response after company attended listening session with FDA Commissioner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925029907/0001437749-25-029907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925029907/nrxp20250926_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-029907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer